Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex
Background: Rifamycins are the cornerstone of anti-tuberculosis therapy while they are potent inducers of drug metabolizing enzymes. For the first time, we evaluated the effect of rifampicin (RIF) and rifabutin (RBT) on the pharmacokinetics (PK) of dolutegravir (DTG) in patients with HIV and tubercu...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971222000029 |
| _version_ | 1831642424650235904 |
|---|---|
| author | Xiaoqin Le Xiaoye Guo Jianjun Sun Li Liu Yinzhong Shen Jiangrong Wang Tangkai Qi Zhenyan Wang Yang Tang Wei Song Lin Yin Lijun Zhang Renfang Zhang Jun Chen |
| author_facet | Xiaoqin Le Xiaoye Guo Jianjun Sun Li Liu Yinzhong Shen Jiangrong Wang Tangkai Qi Zhenyan Wang Yang Tang Wei Song Lin Yin Lijun Zhang Renfang Zhang Jun Chen |
| author_sort | Xiaoqin Le |
| collection | DOAJ |
| description | Background: Rifamycins are the cornerstone of anti-tuberculosis therapy while they are potent inducers of drug metabolizing enzymes. For the first time, we evaluated the effect of rifampicin (RIF) and rifabutin (RBT) on the pharmacokinetics (PK) of dolutegravir (DTG) in patients with HIV and tuberculosis (TB)/ mycobacterium avium complex (MAC) co-infection. Methods: Both HIV/TB (or MAC) co-infected patients and HIV infected patients without TB/MAC were enrolled. Patients in the RIF group received DTG 50 mg twice daily together with 600mg of RIF, while patients in the RBT group received DTG 50 mg once daily together with 300 mg of RBT. The DTG pharmacokinetic profiles in different groups were assessed. Results: A total of 13 subjects in the RIF group, 12 subjects in the RBT group, and 10 subjects in non-TB/MAC group were enrolled. The geometric mean ratio (GMR) of the trough concentration (Ctr) of DTG in the RIF group to non-TB/MAC group was 1.33 [90% confidence interval (CI):0.97 to 1.81], while the GMR of the maximum concentration (Cmax) of DTG was 1.29 (90% CI: 1.23 to 1.36). The GMR of the Ctr of DTG in the RBT group to non-TB/MAC group was 0.41 (90% CI: 0.30 to 0.57), while the GMR of the Cmax of DTG was 0.55 (90% CI: 0.52 to 0.57). Conclusions: Due to the relatively low trough concentrations of DTG with RBT, DTG 50mg once daily together with RBT could only serve as an alternative option for HIV/TB (or MAC) co-infected patients. |
| first_indexed | 2024-12-19T12:41:55Z |
| format | Article |
| id | doaj.art-0e21abc0daed4cf88e35bc3a44a1f6a7 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-19T12:41:55Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-0e21abc0daed4cf88e35bc3a44a1f6a72022-12-21T20:20:57ZengElsevierInternational Journal of Infectious Diseases1201-97122022-03-01116147150Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complexXiaoqin Le0Xiaoye Guo1Jianjun Sun2Li Liu3Yinzhong Shen4Jiangrong Wang5Tangkai Qi6Zhenyan Wang7Yang Tang8Wei Song9Lin Yin10Lijun Zhang11Renfang Zhang12Jun Chen13Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaThe Fifth People's Hospital of Wuxi City, Jiangsu ProvinceDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Alternative Correspondence author: Renfang Zhang, Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jinshan District, Shanghai 201508, China; Tel: +86-21-37990333.Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Correspondence author: Jun Chen, Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jinshan District, Shanghai 201508, China; Tel: +86-021-37990333.Background: Rifamycins are the cornerstone of anti-tuberculosis therapy while they are potent inducers of drug metabolizing enzymes. For the first time, we evaluated the effect of rifampicin (RIF) and rifabutin (RBT) on the pharmacokinetics (PK) of dolutegravir (DTG) in patients with HIV and tuberculosis (TB)/ mycobacterium avium complex (MAC) co-infection. Methods: Both HIV/TB (or MAC) co-infected patients and HIV infected patients without TB/MAC were enrolled. Patients in the RIF group received DTG 50 mg twice daily together with 600mg of RIF, while patients in the RBT group received DTG 50 mg once daily together with 300 mg of RBT. The DTG pharmacokinetic profiles in different groups were assessed. Results: A total of 13 subjects in the RIF group, 12 subjects in the RBT group, and 10 subjects in non-TB/MAC group were enrolled. The geometric mean ratio (GMR) of the trough concentration (Ctr) of DTG in the RIF group to non-TB/MAC group was 1.33 [90% confidence interval (CI):0.97 to 1.81], while the GMR of the maximum concentration (Cmax) of DTG was 1.29 (90% CI: 1.23 to 1.36). The GMR of the Ctr of DTG in the RBT group to non-TB/MAC group was 0.41 (90% CI: 0.30 to 0.57), while the GMR of the Cmax of DTG was 0.55 (90% CI: 0.52 to 0.57). Conclusions: Due to the relatively low trough concentrations of DTG with RBT, DTG 50mg once daily together with RBT could only serve as an alternative option for HIV/TB (or MAC) co-infected patients.http://www.sciencedirect.com/science/article/pii/S1201971222000029HIVtuberculosispharmacokineticsdolutegravirrifampicinrifabutin |
| spellingShingle | Xiaoqin Le Xiaoye Guo Jianjun Sun Li Liu Yinzhong Shen Jiangrong Wang Tangkai Qi Zhenyan Wang Yang Tang Wei Song Lin Yin Lijun Zhang Renfang Zhang Jun Chen Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex International Journal of Infectious Diseases HIV tuberculosis pharmacokinetics dolutegravir rifampicin rifabutin |
| title | Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex |
| title_full | Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex |
| title_fullStr | Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex |
| title_full_unstemmed | Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex |
| title_short | Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex |
| title_sort | pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis mycobacterium avium complex |
| topic | HIV tuberculosis pharmacokinetics dolutegravir rifampicin rifabutin |
| url | http://www.sciencedirect.com/science/article/pii/S1201971222000029 |
| work_keys_str_mv | AT xiaoqinle pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT xiaoyeguo pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT jianjunsun pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT liliu pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT yinzhongshen pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT jiangrongwang pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT tangkaiqi pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT zhenyanwang pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT yangtang pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT weisong pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT linyin pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT lijunzhang pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT renfangzhang pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex AT junchen pharmacokineticfeaturesofdolutegravirwithrifampicinandrifabutinamongpatientscoinfectedwithhumanimmunodeficiencyvirusandtuberculosismycobacteriumaviumcomplex |